

3425 Corporate Way • Duluth GA 30096 USA 770.446.5483 • Fax: 770.441.2237 www.gdx.net/www.metametrix.com

Date Collected: 6/9/13

Date Received: 6/12/13

Report Date: 6/26/13

2105 GI Effects® Microbial Ecology Profile - Stool

Methodology: DNA Analysis, GC/MS, Microscopic, Colorimetric, Automated Chemistry, ELISA

Consistency = Formed/Normal



E+007 **Predominant Bacteria** E+007 Obligate anaerobes 1.6 3.7 >= 1.3 Bacteroides sp. 1.5 6.2 5.5 >= 1.0 Clostridia sp. 1.6 6.2 6.6 >= 1.1 Prevotella sp. 7.4 1.6 4.9 >= 1.1 Fusobacteria sp. 1.6 5.8 Streptomyces sp. 8.2 >= 1.0 1.7 6.2 >= 1.2 6.1 Mycoplasma sp. Facultative anaerobes 1.8 7.8 3.6 Lactobacillus sp. 7.6 2.3 2.5 >= 1.8 Bifidobacter sp. Obligate aerobes 1.7 3.8 Escherichia coli (E. coli)

Units and Reference Ranges

Organisms are detected by DNA analysis. One colony forming unit (CFU) is equivalent to one bacterium. Each genome detected represents one cell, or one CFU. Results are expressed in scientific notation, so an organism reported as 2.5 E7 CFU/gram is read as 25 million colony forming units per gram of feces. The cutoff for significance of Opportunistic Bacteria has been set at 1.0E+ 005 (100,000). These are levels above which clinically significant growth may be present. Rather than reporting semi-quantitative +1 to +4 levels, the new methodology provides full quantitative analysis.

Predominant Bacteria play major roles in health. They provide colonization resistance against potentially pathogenic organisms, aid in digestion and absorption, produce vitamins and SCFA's, and stimulate the GI immune system. DNA probes allow detection of multiple species (sp.) within a genus, so the genera that are reported cover many species.

Opportunistic Bacteria

No clinically significant amounts.

Opportunistic Bacteria may cause symptoms and be associated with disease. They can affect digestion and absorption, nutrient production, pH and immune state. Antibiotic sensitivity tests will be performed on all opportunistic bacteria found, although clinical history is usually considered to determine treatment since the organisms are not generally considered to be pathogens.



3425 Corporate Way • Duluth GA 30096 USA 770.446.5483 • Fax: 770.441.2237 www.gdx.net/www.metametrix.com

Date Collected: 6/9/13

Date Received: 6/12/13

Report Date: 6/26/13

Methodology: DNA Analysis, GC/MS, Microscopic, 2105 GI Effects® Microbial Ecology Profile - Stool Colorimetric, Automated Chemistry, ELISA 95% Pathogenic Bacteria Reference < 0.01 Helicobacter pylori <=1.0E+005 E. coli 0157:H7 < 0.01 <=1.0E+005 < 0.01 <=1.0E+005 Clostridium difficile < 0.01 <=1.0E+005 Campylobacter sp. Expected Yeast/Fungi Yeast/Fungi Value Yeast overgrowth has been linked to many chronic conditions, in part because of antigenic +2 => 1000 pg DNA/g specimen Saccharomyces sp. Neg responses in some patients to even low rates of yeast growth. Potential symptoms include diarrhea, headache, bloating, atopic dermatitis, and fatigue. Positives are reported as +1, +2, +3 or +4 indicating >100, >1000, >10000 or >100000 pg DNA/g. Expected **Parasites** Value **Parasites** No Ova or Parasites Parasite infections are a major cause of non-viral diarrhea. Symptoms may include constipation, gas, bloating, increased allergy response, colitis, nausea, and distention. Adiposity Index The Adiposity Index is derived by using DNA probes that detect multiple genera of the 59 Firmicutes phyla Firmicutes and Bacteroidetes. Abnormalities of these phyla may be associated Bacteroidetes 41 with increased caloric extraction from food. **Drug Resistance Genes Drug Resistance Genes** aacA, aphD - Gentamycin, Kanamycin, and aacA, aphD Neg gyrB, ParE Neg Tobramycin mecA - Methicillin PBP1a, 2B Neg Neg mecA VanA, vanB, vanC - Vancomycin and Teicoplanin Neg vanA, B, and C GyrB, ParE - Ciprofloxacin and later quinolones

Decisions involving diagnosis and treatment are the responsibility of the clinician.

PBP1a, PBP2B - Penicillin



 Date Collected:
 06/09/2013

 Date Received:
 06/12/2013

 Date of Report:
 06/26/2013



2155 GI Effects® Sensitivity Fungi Profile - Stool

Methodology: DNA Analysis, ELISA

Pharmaceuticals	Sensitive		Resistant
1. Amphotericin	S		
2. Fluconazole			R
3. Itraconazole			R
4. Ketoconazole	S		
5. Nystatin	S		
Botanicals	Sensitive	0	Resistant
5-Hydroxy-1,4-naphthoquinone Black Walnut	S		
7 400	0		

Agents marked as "Sensitive" cause effective fungal growth suppression. Those antifungal agents are candidates for suppressing the growth of fungi

Agents indicated as "Resistant" have low effectiveness and can increase the risk of inducing drug resistant organisms. If all tested agents are "Resistant," synergistic mixtures of antifungal agents may be effective.

all organisms reported under "Yeast/Fungi."

and yeasts in the patient's colon. The results apply to

Fungal growth suppression is measured in a

introduced before incubation. In contrast to the older

liquid growth medium where bacterial growth is

suppressed and specific antifungal agents are

isolation and culture techniques, such universal

antifungals in the complex milieu of the colon.

culturing more closely approximates the actions of

For Botanical sensitivity testing the active ingredients are tested and an example of the available source is shown.

Sensitivities are not performed on "Pathogens" or "Parasites" because they do not grow in culture under normal laboratory conditions. Standard protocols are generally used for treatment of pathogens and parasites.

Botanicals	Sensitive	F	Resistant
6. 5-Hydroxy-1,4-naphthoquinone Black Walnut	S		
7. Alliin Garlic	S		
8. Arbutin Uva Ursi			R
Artemisinin Wormwood			R
10. Berberine Goldenseal	S		
11. Caprylic acid Octanoic acid	S		
12. Carvacrol Oregano	S		
13. Oleuropein Olive Leaf			R
14. Quinic Acid Cats Claw	S		
15. Thymol Oil of Thyme			R
16. Undecylenic acid Undecylenic acid			R